A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
- Status
- UNKNOWN
- Phase
- N/A
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
- Status
- COMPLETED
- Phase
- N/A
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Status
- RECRUITING
- Phase
- PHASE3
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- Status
- UNKNOWN
- Phase
- N/A
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA